올릭스
97,600KRWMarket close of 10/20 (Tue)
Down -4.03%-4,100KRWMarket close of 10/20 (Tue)
Preliminary value right after the close — replaced by official KRX data tomorrow morningClose of 10/21 (Wed)106,900KRWUp +9.53%
Preliminary · just after the close · replaced by official KRX data tomorrow morning
- Open
- 99,600
- High
- 102,400
- Low
- 93,300
- Day range
- Day range low 93,300 high 102,400, open 99,600, close 97,600, previous close 101,700
- Volume
- 20×10K shares
- 19.1B KRW 0.71× the 20-session average
Market close of 10/20 (Tue)
Where it sits in the 1-year range
9%1-year close range 87,300 to 207,000 won, 9% up from the low
9% of the way up from the lowest close in 1 year (252 sessions) · -52.9% from the high
Something to check
1 to check: operating loss
Free · no sign-inSource from 2021-05-17
Points to check
- Earningsto check-41.6B KRWOperating income over the last four quarters -41.6B KRW (loss)
- Daily moveusual range-4.03%-4.03%, 0.9× the usual (20-session average ±4.67%)That day -4.03% · usual ±4.67% · large-move threshold ±9.3%
- Trading valueusual range0.7×19.1B KRW, 0.7× the 20-session average0.71× the 20-session average · check threshold 3×
The other 3 are within the usual range
- Recent filings0Last 14 days
- Foreign & institutional+2.3B KRWusual range
- Data date10/20 (Tue)Market close
See the full check report
Same sector · 바이오 R&D
Down -2.19%· 16 of 64 stocks up, preferred shares excluded · trading value 190.5B KRW
| Stock | 20D | Change | Trading value |
|---|---|---|---|
| 알테오젠 | Close over the last 20 sessions -9.6% | Down -3.35% | 51.1B KRW |
| 디앤디파마텍 | Close over the last 20 sessions -11.8% | Down -1.93% | 15.1B KRW |
| 리가켐바이오 | Close over the last 20 sessions -15.4% | Down -1.41% | 12.1B KRW |
| 프로티나 | Close over the last 20 sessions +31.8% | Up +7.38% | 10.0B KRW |
| 바이오인프라 | Close over the last 20 sessions +123.3% | Down -6.80% | 9.3B KRW |
Schedule
- Q3 report due · 11/16 (Mon) · in 26 days
- Next data 10/22 (Thu) after 08:50
For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.